T1	Participants 39 119	previously treated patients with refractory advanced non-small-cell lung cancer:
T2	Participants 133 229	a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).
T3	Participants 242 281	This placebo-controlled phase III study
T4	Participants 360 446	treatment for patients with locally advanced or metastatic non-small-cell lung cancer.
T5	Participants 942 996	1129 patients were assigned gefitinib and 563 placebo.
T6	Participants 1236 1268	812 patients with adenocarcinoma
T7	Participants 1741 1807	significant improvement in survival in either coprimary population
T8	Participants 1903 1971	evidence of benefit among never-smokers and patients of Asian origin
